GLF
REGN icon

Groupe la Francaise’s Regeneron Pharmaceuticals REGN Stock Holding History

Groupe la Francaise’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$303K Sell
442
-2,806
-86% -$2.15M ﹤0.01% 356
2025
Q4 		$2.28M Sell
3,248
-783
-19% -$532K 0.03% 239
2025
Q3 		$2.06M Sell
4,031
-325
-7% -$184K 0.03% 245
2025
Q2 		$2.28M Sell
4,356
-3,671
-46% -$2.05M 0.04% 218
2025
Q1 		$4.92M Sell
8,027
-8,034
-50% -$5.53M 0.1% 134
2024
Q4 		$11.7M Buy
+16,061
New +$13.5M 0.29% 54

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Groupe la Francaise's REGN Position: Q1 2026 in Review

Groupe la Francaise reduced its Regeneron Pharmaceuticals (REGN) stake by 86% in Q1 2026, selling an estimated $2.15M and leaving 442 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #356.

Groupe la Francaise first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $11.7M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Groupe la Francaise held 442 shares of Regeneron Pharmaceuticals worth $303K as of Q1 2026.
  • Groupe la Francaise sold 2,806 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.15M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Groupe la Francaise's portfolio in Q1 2026, its #356 holding.
  • Groupe la Francaise first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Groupe la Francaise's Regeneron Pharmaceuticals position peaked at $11.7M in Q4 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Groupe la Francaise's 13F filing for Q1 2026, filed 21 May 2026.